Clinical trials: System Sclerosis
ALS, Amyotrophic Lateral Sclerosis
NYSCF Scientific Discovery Biobank
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells…
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset
- Trial name
- NCT06203106
- Testing
- Biological Sample Collection
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- New York Stem Cell Foundation Research Institute
Cerebral Cortex Dysfunction
Brain Function in Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis
This study will test whether primary lateral sclerosis (PLS) and amyotrophic lateral sclerosis (ALS) affect parts of the brain responsible for thinking, planning, memory and emotion.
- Trial name
- NCT00334516
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Sclerosis
Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)
This is a multi-centre, double blind, randomised, placebo controlled, parallel group, phase 4 pilot study investigating colecalciferol (vitamin D3) as an add-on treatment to subcutaneously administered interferon-beta-1b in…
- Trial name
- NCT01339676
- Testing
- Colecalciferol
- Where
- Finland
- Volunteers
- 70 people
- Sponsor
- University of Turku
Amyotrophic Lateral Sclerosis
Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day
R(+) pramipexole dihydrochloride monohydrate [R(+)PPX], an experimental neuroprotective drug, is provided in this open label extension study to ALS patients who have participated in earlier clinical protocols.
- Trial name
- NCT00596115
- Testing
- R(+) pramipexole dihydrochloride monohydrate
- Sponsor
- Bennett, James P., Jr., M.D., Ph.D.
Interstitial Lung Diseases, Systemic Sclerosis Associated Interstitial Lung Disease
A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis
This post-approval registry study is planned to generate data to address remaining questions on long-term effectiveness and to better characterize longer term beneficial effects of Nintedanib in patients with systemic sclerosis…
- Trial name
- NCT07080125
- Testing
- Ofev®
- Where
- Switzerland
- Volunteers
- 2,000 people
- Sponsor
- Boehringer Ingelheim
Amyotrophic Lateral Sclerosis
Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral Sclerosis
To evaluate the safety and effectiveness of intravenous infusion of plasma from healthy young people for the treatment of amyotrophic lateral sclerosis.
- Trial name
- NCT04454840
- Testing
- Plasma from healthy young people treatment + Riluzole, Riluzole
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University Third Hospital
Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis
Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
This is an investigator-initiated trial to evaluate the efficacy and safety of BCMA/CD70-targeted CAR-T in the treatment of refractory pediatric rheumatic diseases.
- Conditions
- Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis, Systemic Sclerosis (SSc), Primary Sjogren's Syndrome
- Trial name
- NCT07184450
- Testing
- BCMA/CD70-targetd CAR-T
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Multiple Sclerosis
Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system, usually presenting as clinically isolated syndrome (CIS).
- Trial name
- NCT05072691
- Testing
- CSF immunoglobulin (Ig) free light chains (FLC) dosage
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Francis Corazza
Multiple Sclerosis
Open-Label Natalizumab Safety Extension Study
The primary objective of this study is to determine the safety and the immunogenicity of extended treatment with natalizumab when administered at a dose of 300 mg intravenously (IV) to subjects with multiple sclerosis (MS) who…
- Trial name
- NCT00276172
- Testing
- Natalizumab
- Where
- United States
- Volunteers
- 1,615 people
- Sponsor
- Biogen
Progressive Multiple Sclerosis
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS.
- Trial name
- BOBCAT (NCT07139743)
- Testing
- Obecabtagene autoleucel (obe-cel)
- Where
- 7 sites in United States, Spain and 1 more
- Volunteers
- 24 people
- Sponsor
- Autolus Limited
Chronic Optic Neuropathy in Multiple Sclerosis
CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSIS
Patients with multiple sclerosis (MS) may show chronic signs of optic neuropathy (CON) that may follow acute optic neuritis (secondary form of CON, S-CON) or occur independently of any acute demyelinating lesion of the optic…
- Trial name
- NCT02543788
- Testing
- • Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG
- Where
- France
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Systemic Sclerosis
Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis
We propose to examine several angiogenic/angiostatic mediators in the skin and serum of subjects with SSc and compare it to levels found in the skin and serum of healthy subjects.
- Trial name
- NCT00668473
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Multiple Sclerosis
DECISIve - DiagnosE Using the Central veIn SIgn v1.0
DECISIve - DiagnosE using the Central veIn SIgn. A prospective diagnostic superiority study comparing T2* MRI and lumbar puncture in patients presenting with possible Multiple Sclerosis
- Trial name
- DECISiVE (NCT05533905)
- Testing
- Lumbar puncture, MRI
- Where
- United Kingdom
- Volunteers
- 113 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)
Combined Growth Differentiation Factor-15 (GDF-15) and Lung Ultrasound for ILD Screening in Rheumatoid Arthritis and Systemic Sclerosis
The goal of this observational study is to detect the lung affection in patients with Rheumatoid Arthritis(RA) or Systemic sclerosis (SSc) before appearance of symptoms(Subclinical) using combined diagnostic modalities which are…
- Conditions
- Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Interstitial Lung Disease (ILD)
- Trial name
- NCT07839221
- Testing
- Lung ultrasound, GDF-15 level (ELISA), CT scan
- Volunteers
- 110 people
- Sponsor
- Assiut University
Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs)
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically…
- Conditions
- Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA
- Trial name
- NCT06991114
- Testing
- Allogeneic NK Cells
- Where
- 52 sites in United States, Brazil and 9 more
- Volunteers
- 90 people
- Sponsor
- Artiva Biotherapeutics, Inc.
Multiple Sclerosis
MSFC Versus DAM. A Smartphone Application for Multiple Sclerosis Self-assessment.
Multiple Sclerosis Functional Composite score (MSFC) is one of the gold standard for multiple sclerosis (MS) patient clinical evaluation.
- Trial name
- DAM (NCT02814487)
- Volunteers
- 30 people
- Sponsor
- Ad scientiam
Scleroderma, Systemic
microRNAs in Systemic Scleroderma
No studies have investigated the expression of miRNAs in Dig-ScS tissues. In the absence of specific treatment for this frequent impairment in this connectivity, the team proposes to study miRNA profiles in the esophagus and…
- Trial name
- Dig-ScS (NCT04148716)
- Testing
- additional biopsies
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Multiple Sclerosis
Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells
Determine the in-vivo mechanism of action of INF-B-1b as it's mechanisms of action are not completely understood. We propose that high dose exogenous recombinant IFN-B-1b induces tolerizing effect on DC-dependent T-cell…
- Trial name
- NCT00630721
- Testing
- IFNbeta-1b
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Multiple Sclerosis
Remote Ischemic Conditioning in PPMS
Progressive MS remains the most difficult therapeutic challenge. Remyelination is a promising therapeutic strategy but an effective pharmacologic intervention remains elusive.
- Trial name
- NCT06171334
- Testing
- Remote ischemic conditioning
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- University of Calgary
Multiple Sclerosis, Relapsing-Remitting
An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)
This is a prospective, non-interventional, multicenter study to evaluate quality of life (QoL) and influence of cognitive status on QoL in subjects with relapsing-remitting multiple sclerosis (RRMS) during two years of treatment…
- Trial name
- MusiClock (NCT01110993)
- Where
- Poland
- Volunteers
- 65 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.